23andMe Holding (ME) has provided an announcement.
Bill Richards, a key executive at a company, is set to resign on August 23, 2024, with a severance package including half a year’s salary, healthcare benefits, and accelerated stock vesting. Concurrently, the company is shutting down its Therapeutics Discovery division as of August 9, 2024, which will lead to 30 layoffs, though they anticipate no significant financial repercussions. The remaining Therapeutics segment will focus on advancing its clinical development programs.
See more insights into ME stock on TipRanks’ Stock Analysis page.
